Aided by image-guided validation of the inhibition in both 3D organotypic assays in vitro and intravital imaging of the primary tumor in vivo, several additional upstream or downstream targets can be assessed reliably in this manner in the future using the Akt-FRET biosensor mouse. This evidence concerns the gene AKT1 and neoplasm.